12 Best 52-Week High Stocks to Buy Right Now

3. Centessa Pharmaceuticals plc (NASDAQ:CNTA)

52 Week Range: $9.60 – $29.99

Current Share Price as of December 4: $29.69

Year to date Gain: 65.60%

Stock Upside Potential: 29.17%

Number of Hedge Fund Holders: 40

Centessa Pharmaceuticals plc (NASDAQ:CNTA) is one of the best 52-week high stocks to buy right now. On December 1, B. Riley boosted its price target on Centessa Pharmaceuticals plc (NASDAQ:CNTA) to $42 from $33 and reiterated its Buy rating after impressive Phase 2 data for ORX750.

The CRYSTAL-1 study showed strong wake-promoting effects at much lower doses than competing drugs, with meaningful benefits in narcolepsy type 2 and idiopathic hypersomnia: including an 87% drop in cataplexy episodes, and a clean safety profile. Analysts pointed to Centessa’s potential lead over other developers, rising investor support, and a growing market for orexin-based therapies, especially as the Alkermes-Avadel merger highlights momentum in the space ahead of expected launches starting in 2026.

Previously on November 18, analysts at Guggenheim lifted their price target of the stock to $43 from $28 while reiterating a Buy rating. The price target hike follows the company’s topline results from its ORX750 CRYSTAL-1 Phase 2a study. According to Guggenheim, Centessa remains well-positioned to advance ORX750 in pivotal trials following an equity financing that raised $619 million in pro forma cash. Development of the candidate drug could expand its addressable market by targeting neurodegenerative and neuropsychiatric disorders.

Centessa Pharmaceuticals plc (NASDAQ:CNTA) is a pharmaceutical company that discovers and develops transformational medicines for patients with high unmet needs. Its key programs include a hemophilia program, an orexin agonist program for sleep-wake disorders like narcolepsy, and an immune-oncology program.